Browsing Tag
Wegovy
37 posts
Can Camurus’ once-monthly semaglutide depot reshape the future of obesity and diabetes treatment?
Camurus reports positive Phase 1b results for CAM2056, a monthly semaglutide depot, showing 9.3% weight loss and strong A1c reduction. Read the full data.
Novo Nordisk taps Emcure Pharmaceuticals to launch Poviztra in India as second brand of Wegovy
Novo Nordisk partners with Emcure Pharmaceuticals to launch Poviztra, a second brand of Wegovy, in India. Discover how this could reshape obesity treatment access.
Hims & Hers Health plunges 11% after CEO Andrew Dudum offloads $11m in stock
Shares of Hims & Hers Health fell 11% after CEO Andrew Dudum disclosed a multimillion-dollar stock sale. Find out what’s worrying investors next.
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competition—see how dosing, dual-agonist design, and payer rules define the next pharma showdown.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.
Novo Nordisk eyes FDA approval for high-dose 7.2mg Wegovy after STEP UP trial shows 21% weight loss
Novo Nordisk seeks U.S. approval for 7.2mg Wegovy after 21% average weight loss in trials. Can it outpace Eli Lilly’s Zepbound in the obesity drug race?
Why CVS Caremark’s decision to drop Zepbound could reshape the billion-dollar weight-loss drug war
CVS Caremark faces a lawsuit after dropping Eli Lilly’s Zepbound from coverage. Explore patient, investor, and payer implications in the GLP-1 market battle.
Novo Nordisk stock rises on Wegovy STEER data: Can semaglutide cement its lead over Eli Lilly?
Novo Nordisk shares gained after STEER study showed Wegovy cut heart risks by 57% over tirzepatide. Find out why semaglutide may lead the GLP-1 race.
Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead
Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.